Aditxt Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Aditxt hat ein Gesamteigenkapital von $4.4M und eine Gesamtverschuldung von $9.0M, was einen Verschuldungsgrad von 202% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $29.8M bzw. $25.4M.

Wichtige Informationen

202.0%

Verhältnis von Schulden zu Eigenkapital

US$8.99m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$328.60k
Eigenkapital	US$4.45m
Gesamtverbindlichkeiten	US$25.39m
Gesamtvermögen	US$29.84m

Jüngste Berichte zur Finanzlage

Recent updates

Aditxt gains on regaining compliance with Nasdaq listing requirements

Sep 29

Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split

Sep 13

Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate

Jul 08

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ADTXDie kurzfristigen Aktiva des Unternehmens ($2.1M) decken seine kurzfristigen Passiva ($24.4M) nicht.

Langfristige Verbindlichkeiten: ADTXDie kurzfristigen Vermögenswerte des Unternehmens ($2.1M) übersteigen seine langfristigen Verbindlichkeiten ($1.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ADTXDie Nettoverschuldung im Verhältnis zum Eigenkapital (194.6%) wird als hoch angesehen.

Schulden abbauen: ADTX hatte vor 5 Jahren ein negatives Eigenkapital, ist jetzt aber positiv und hat sich somit verbessert.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: ADTX verfügt auf der Grundlage des zuletzt gemeldeten freien Cashflows über eine ausreichende Liquiditätsreserve für 0 Monate. [freien Cashflow]], hat aber seitdem zusätzliches Kapital aufgenommen.

Vorhersage Cash Runway: Es wird prognostiziert, dass ADTX auf Grundlage der Schätzungen des freien Cashflows über ausreichend Liquidität für 0 Monate verfügt, das Unternehmen hat seitdem jedoch weiteres Kapital aufgenommen.

Aditxt Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Aditxt, Inc. announced delayed 10-Q filing

Aditxt Receives Non-Compliance Letter Regarding Nasdaq Minimum Bid Price Requirements

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. announced delayed annual 10-K filing

Aditxt Regains Compliance with Nasdaq Stockholders' Equity Requirement

Recent updates

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. Appoints Sylvia Hermina to its Board of Directors

Aditxt Receives Non-Compliance Letter Regarding Nasdaq Minimum Bid Price Requirements

Aditxt, Inc. has filed a Follow-on Equity Offering in the amount of $35 million.

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. has filed a Follow-on Equity Offering in the amount of $1.197058 million.

Aditxt, Inc. announced that it has received $0.5 million in funding

Aditxt, Inc., Annual General Meeting, Aug 07, 2024

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. announced that it expects to receive $4.2 million in funding

Aditxt, Inc. announced delayed annual 10-K filing

Aditxt, Inc. announced that it has received $6.000003 million in funding

Aditxt Regains Compliance with Nasdaq Stockholders' Equity Requirement

Aditxt, Inc. (NasdaqCM:ADTX) entered into an agreement and plan of merger to acquire Evofem Biosciences, Inc. (OTCPK:EVFM) from shareholders.

Third quarter 2023 earnings released: US$47.13 loss per share (vs US$211 loss in 3Q 2022)

Aditxt, Inc. Announces Board Changes

Nasdaq Hearings Panel Grants Aditxt an Exception through December 26, 2023 to Allow Aditxt to Complete its Plan to Demonstrate Compliance with the Equity Rule

Aditxt Receives Written Notice from Nasdaq

Aditxt, Inc. announced that it has received $10 million in funding

Aditxt, Inc. announced that it expects to receive $10 million in funding

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$6.42 loss in 2Q 2022)

Insufficient new directors

Aditxt, Inc. Announces Resignation of Matthew Shatzkes as Chief Legal Officer, General Counsel and Corporate Secretary

Aditxt, Inc., Annual General Meeting, Aug 16, 2023

Aditxt Receives Notice from Nasdaq Due to Non-Compliance with Minimum Stockholders Equity Requirement

Aditxt, Inc. Announces Development and Publication of Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection

Aditxt Regains Compliance with Nasdaq Listing Requirements

Aditxt gains on regaining compliance with Nasdaq listing requirements

Aditxt, Inc. has completed a Follow-on Equity Offering.

Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split

Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials

Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate

Aditxt, Inc., Annual General Meeting, Jun 24, 2022

Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron

Aditxt Provides Update on AditxtReprogramming’s Apoptotic DNA Immunotherapy Therapeutic Platform

High number of new directors

Aditx Therapeutics, Inc. Announces Enhancements to Its Aditxtscore for COVID-19

Aditxt adds Lauren Chung to board of directors

Co-Founder exercised options to buy US$60k worth of stock.

Eazy Testing Inc. Becomes AditxtScore™ Channel Partner, to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring with its Walk-In, Concierge, and Pre-Flight Services

New 90-day high: US$4.10

ADiTx Therapeutics, Inc. Appoints Dolly B. Tyan as Senior Vice President of Clinical Development - Transplantation

Aditx Therapeutics, Inc. Announces the Operational Launch of the AditxtScore™ Immune Monitoring Platform

New 90-day high: US$2.61

Aditxt Signs Distribution Agreement with Todos Medical Ltd. for Aditxtscore™ for Covid-19 Immune Monitoring Service

Aditxt, Todos Medical in distribution pact for for COVID-19 immune monitoring

New 90-day high: US$2.39

We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth

Aditx Therapeutics, Inc. Appoints Anthony Voorhies as Head of Business Development for AditxtScore

Aditx Therapeutics, Inc. Secures CLIA Certification for AditxtScore™ Laboratory Operations in Richmond, VA, and Plans to Launch AditxtScore™ for COVID-19 as a Lab Developed Test

ADiTx Therapeutics, Inc. has completed a Composite Units Offering in the amount of $9.6 million.

ADiTx Therapeutics, Inc. has completed an IPO in the amount of $11.040012 million.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen